Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services, has established a U.S.-based subsidiary for its Contract Development and Manufacturing Services, which will operate under the name Scinai Bioservices Inc.
 
Scinai’s new U.S. subsidiary, Scinai Bioservices Inc., aims to serve U.S.-based early-stage biotech companies by providing the required CDMO services that are currently in short supply. Moreover, Scinai Bioservices Inc. allows early-stage biotech startups, supported by U.S. government grant funding, to use their grant money by contracting with them, avoiding any concerns related to the BIOSECURE Act.
 
Scinai’s CDMO business unit is focused on rapid growth, acquiring new clients, and building its reputation and brand awareness. The company expects revenues from the CDMO business to increase materially in the coming years.
 
Amir Reichman, CEO of Scinai, commented: “We are thrilled and energized by the opening of our new subsidiary in the U.S. Last week, we signed our first contract with U.S. customer, Serpin Pharma, to support their clinical manufacturing. I believe that our expanded presence in the U.S. will significantly enhance the prospects of our CDMO unit.”